Analysis of the key themes driving M&A activity reveals that regenerative medicine accounted for 4 pharmaceutical deals announced in Q2 2023, worth a total value of $310m. The $309.6m acquisition of Sigilon Therapeutics by Eli Lilly and Co was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q2 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.

In value terms, regenerative medicine-related deal activity remained flat in Q2 2023 compared with the previous quarter and as compared to Q2 2022. Related deal volume increased by 300% in Q2 2023 versus the previous quarter and was 100% higher than in Q2 2022.

The top-ranked financial advisors supporting these M&A deals in Q2 2023 were Evercore; Guggenheim Partners; Houlihan Lokey with 1, 1, 1 deals respectively.

The top-ranked legal advisors supporting these M&A deals in Q2 2023 were Goodwin Procter; Cooley; Gibson, Dunn & Crutcher with 2, 1, 1 deals respectively.

For further understanding of Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2023 – Thematic Intelligence, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.